Bosentan

Kelly Chin, Richard Channick

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Bosentan (Tracleer®, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period. Follow-up data over 3 years has shown few deteriorations, with the majority of patients maintaining their response to bosentan alone. Investigations exploring the use of bosentan as an add-on agent to intravenous epoprostenol (Flolan®, GlaxoSmithKline Plc) in those with the most severe disease are ongoing. Bosentan may also have antifibrotic properties and its use in pulmonary fibrosis is being explored. Ease of administration of bosentan with twice-daily oral dosing will provide many patients with pulmonary hypertension an option for treatment without the risks and discomforts of continuous intravenous medication.

Original languageEnglish (US)
Pages (from-to)175-182
Number of pages8
JournalExpert Review of Cardiovascular Therapy
Volume2
Issue number2
DOIs
StatePublished - Mar 2004

Fingerprint

Epoprostenol
Pulmonary Hypertension
Pulmonary Fibrosis
bosentan
Hemodynamics
Placebos
Pharmaceutical Preparations
Therapeutics
Endothelin Receptor Antagonists

Keywords

  • Bosentran
  • Endothelin antagonists
  • Pulmonary arterial hypertension

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Bosentan. / Chin, Kelly; Channick, Richard.

In: Expert Review of Cardiovascular Therapy, Vol. 2, No. 2, 03.2004, p. 175-182.

Research output: Contribution to journalArticle

Chin, Kelly ; Channick, Richard. / Bosentan. In: Expert Review of Cardiovascular Therapy. 2004 ; Vol. 2, No. 2. pp. 175-182.
@article{632296ce5db9427a85ec94dac924e60f,
title = "Bosentan",
abstract = "Bosentan (Tracleer{\circledR}, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period. Follow-up data over 3 years has shown few deteriorations, with the majority of patients maintaining their response to bosentan alone. Investigations exploring the use of bosentan as an add-on agent to intravenous epoprostenol (Flolan{\circledR}, GlaxoSmithKline Plc) in those with the most severe disease are ongoing. Bosentan may also have antifibrotic properties and its use in pulmonary fibrosis is being explored. Ease of administration of bosentan with twice-daily oral dosing will provide many patients with pulmonary hypertension an option for treatment without the risks and discomforts of continuous intravenous medication.",
keywords = "Bosentran, Endothelin antagonists, Pulmonary arterial hypertension",
author = "Kelly Chin and Richard Channick",
year = "2004",
month = "3",
doi = "10.1586/14779072.2.2.175",
language = "English (US)",
volume = "2",
pages = "175--182",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - Bosentan

AU - Chin, Kelly

AU - Channick, Richard

PY - 2004/3

Y1 - 2004/3

N2 - Bosentan (Tracleer®, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period. Follow-up data over 3 years has shown few deteriorations, with the majority of patients maintaining their response to bosentan alone. Investigations exploring the use of bosentan as an add-on agent to intravenous epoprostenol (Flolan®, GlaxoSmithKline Plc) in those with the most severe disease are ongoing. Bosentan may also have antifibrotic properties and its use in pulmonary fibrosis is being explored. Ease of administration of bosentan with twice-daily oral dosing will provide many patients with pulmonary hypertension an option for treatment without the risks and discomforts of continuous intravenous medication.

AB - Bosentan (Tracleer®, Actelion Pharmaceuticals Ltd) is an oral dual endothelin receptor antagonist approved for use in functional class III to IV pulmonary arterial hypertension. In two placebo-controlled trials, patients receiving bosentan showed improved functional class, 6-minute walk distance and hemodynamics over a 12- to 16-week period. Follow-up data over 3 years has shown few deteriorations, with the majority of patients maintaining their response to bosentan alone. Investigations exploring the use of bosentan as an add-on agent to intravenous epoprostenol (Flolan®, GlaxoSmithKline Plc) in those with the most severe disease are ongoing. Bosentan may also have antifibrotic properties and its use in pulmonary fibrosis is being explored. Ease of administration of bosentan with twice-daily oral dosing will provide many patients with pulmonary hypertension an option for treatment without the risks and discomforts of continuous intravenous medication.

KW - Bosentran

KW - Endothelin antagonists

KW - Pulmonary arterial hypertension

UR - http://www.scopus.com/inward/record.url?scp=2542567909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542567909&partnerID=8YFLogxK

U2 - 10.1586/14779072.2.2.175

DO - 10.1586/14779072.2.2.175

M3 - Article

C2 - 15151466

AN - SCOPUS:2542567909

VL - 2

SP - 175

EP - 182

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 2

ER -